{"name":"Advagene Biopharma Co. Ltd.","slug":"advagene-biopharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AD17002","genericName":"AD17002","slug":"ad17002","indication":"Other","status":"phase_2"},{"name":"Inactivated trivalent influenza vaccine","genericName":"Inactivated trivalent influenza vaccine","slug":"inactivated-trivalent-influenza-vaccine","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AD07010","genericName":"AD07010","slug":"ad07010","indication":"Metastatic non-small cell lung cancer","status":"phase_2"}]}],"pipeline":[{"name":"AD17002","genericName":"AD17002","slug":"ad17002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inactivated trivalent influenza vaccine","genericName":"Inactivated trivalent influenza vaccine","slug":"inactivated-trivalent-influenza-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AD07010","genericName":"AD07010","slug":"ad07010","phase":"phase_2","mechanism":"AD07010 is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaU5fWi1lNUE5QUpxdDBfdmNYUnhfa0lucXJ5d3F4UnRvM3ljT2pzdVVRNHY3TUhLNDBOQ0hHdk5xOFN2Y0pZaTlCWGRVZ2R1VzZ1YWxldkhrdUJRdTBJZ0tRbDlSRXA2ak15ektmemhvNFMycG16eXVNYWdROXRnZTlVQnRJNEthaDRXRTdVNFk5ZjRa?oc=5","date":"2026-04-02","type":"pipeline","source":"openPR.com","summary":"Allergic Rhinitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight - openPR.com","headline":"Allergic Rhinitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQTUxwR0s3WHZNRlJaXzFhOHE2VVlnb1kzeEEtR2VqM0ZBZVNVNklLYUZac1FuR2NLRWRxTmFnc21qLU5ldE02ZVJ3bUR2UUU0QmJGbDJwWnV3cDlFbUV1ZmZhY0NObUx2OXoxNFdxblRQNWRlTHo4UDdSb1JjdGZ4LVhQcXpNajlMakMwcWtqMjNYZGhHcnFJb2Nibm12RFVad2pSeGY2b0NrbERYQzVLckkwR0YzWW5PWlZHZk1LRUE0RnB5ckZDUm42UHdweVRlVk1ldDllQVRUdTJETlQ3eGpwWkJjbW1ndUNiS1BkblNMR3dfRWRWQjZIc3E?oc=5","date":"2024-09-10","type":"pipeline","source":"PR Newswire","summary":"Global Respiratory Monitoring Devices Market to Register Sustainable Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire","headline":"Global Respiratory Monitoring Devices Market to Register Sustainable Growth at a CAGR of ~6% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxObHRZbW5qbUhROVktVlZwYWNoYjRlVEtjME5JVzlWRzFqdlhpLXljMk5BWmRqNXZXbmhpTFpHWlR1QmYtbm5WVEJwQ0xfaVFrTnhvRGNNMnkteHpmRGVvTTNYSnRjY3ZFa0QtLXVSX1Q3VFJLOUFtUTRQTTdhX3ZfWHJ5ZlIwRldIT1VpaER0ZndiekZ0akJvOFZPNFlfb21fU1pFQ0pwNVJqdXRNZVRKTDVCQnZJXy1VVWFTQlE0S0ZzVjRKdW1IVWx3WTdJSERaNzk3alM3Zk53Mmd5QWpRcEQzcEdJWVJ0RktSalJXUGRtZk9reGVTbnhkMmo0SlE?oc=5","date":"2024-08-07","type":"pipeline","source":"GlobeNewswire","summary":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}